Abstract
Candida spp. are the fourth leading cause of bloodstream infections, and non-albicans species are increasing in importance. Micafungin is a new echinocandin antifungal agent with excellent in vitro activity against Candida spp. Pediatric, neonatal, and adult patients with new or refractory candidemia were enrolled into this open-label, noncomparative, international study. The initial dose of micafungin was 50 mg/d (1 mg/kg for patients <40 kg) for infections due to C. albicans and 100 mg/d (2 mg/kg for patients <40 kg) for infections due to other species. Dose escalation was allowed. Maximum length of therapy was 42 days. A total of 126 patients were evaluable (received at least five doses of micafungin). Success (complete or partial response) was seen in 83.3% patients overall. Success rates for treatment of infections caused by the most common Candida spp. were as follows: C. albicans 85.1%, C. glabrata 93.8%, C. parapsilosis 86.4%, and C. tropicalis 83.3%. Serious adverse events related to micafungin were uncommon. Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. Large-scale, randomized, controlled trials are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 654-661 |
| Number of pages | 8 |
| Journal | European Journal of Clinical Microbiology and Infectious Diseases |
| Volume | 24 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jan 1 2005 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
Cite this
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. / Ostrosky-Zeichner, L.; Kontoyiannis, D.; Raffalli, J.; Mullane, K. M.; Vazquez, Jose Antonio; Anaissie, E. J.; Lipton, J.; Jacobs, P.; Van Rensburg, J. H.Jansen; Rex, J. H.; Lau, W.; Facklam, D.; Buell, D. N.
In: European Journal of Clinical Microbiology and Infectious Diseases, Vol. 24, No. 10, 01.01.2005, p. 654-661.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia
AU - Ostrosky-Zeichner, L.
AU - Kontoyiannis, D.
AU - Raffalli, J.
AU - Mullane, K. M.
AU - Vazquez, Jose Antonio
AU - Anaissie, E. J.
AU - Lipton, J.
AU - Jacobs, P.
AU - Van Rensburg, J. H.Jansen
AU - Rex, J. H.
AU - Lau, W.
AU - Facklam, D.
AU - Buell, D. N.
PY - 2005/1/1
Y1 - 2005/1/1
N2 - Candida spp. are the fourth leading cause of bloodstream infections, and non-albicans species are increasing in importance. Micafungin is a new echinocandin antifungal agent with excellent in vitro activity against Candida spp. Pediatric, neonatal, and adult patients with new or refractory candidemia were enrolled into this open-label, noncomparative, international study. The initial dose of micafungin was 50 mg/d (1 mg/kg for patients <40 kg) for infections due to C. albicans and 100 mg/d (2 mg/kg for patients <40 kg) for infections due to other species. Dose escalation was allowed. Maximum length of therapy was 42 days. A total of 126 patients were evaluable (received at least five doses of micafungin). Success (complete or partial response) was seen in 83.3% patients overall. Success rates for treatment of infections caused by the most common Candida spp. were as follows: C. albicans 85.1%, C. glabrata 93.8%, C. parapsilosis 86.4%, and C. tropicalis 83.3%. Serious adverse events related to micafungin were uncommon. Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. Large-scale, randomized, controlled trials are warranted.
AB - Candida spp. are the fourth leading cause of bloodstream infections, and non-albicans species are increasing in importance. Micafungin is a new echinocandin antifungal agent with excellent in vitro activity against Candida spp. Pediatric, neonatal, and adult patients with new or refractory candidemia were enrolled into this open-label, noncomparative, international study. The initial dose of micafungin was 50 mg/d (1 mg/kg for patients <40 kg) for infections due to C. albicans and 100 mg/d (2 mg/kg for patients <40 kg) for infections due to other species. Dose escalation was allowed. Maximum length of therapy was 42 days. A total of 126 patients were evaluable (received at least five doses of micafungin). Success (complete or partial response) was seen in 83.3% patients overall. Success rates for treatment of infections caused by the most common Candida spp. were as follows: C. albicans 85.1%, C. glabrata 93.8%, C. parapsilosis 86.4%, and C. tropicalis 83.3%. Serious adverse events related to micafungin were uncommon. Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. Large-scale, randomized, controlled trials are warranted.
UR - http://www.scopus.com/inward/record.url?scp=27944466696&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27944466696&partnerID=8YFLogxK
U2 - 10.1007/s10096-005-0024-8
DO - 10.1007/s10096-005-0024-8
M3 - Article
C2 - 16261306
AN - SCOPUS:27944466696
VL - 24
SP - 654
EP - 661
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
SN - 0934-9723
IS - 10
ER -